IVA Company Profile and Key Details

Inventiva S.A. (NASDAQ:IVA) closed at $5.80 USD, losing -$0.15 (-2.52%) from the previous close of $5.95. The stock is currently mid-range between its 52-week high and low $2.23 and $7.98. With a market capitalization of about $301.50 million, Inventiva S.A. is classified as a small-cap and shows market-like volatility (beta ~0.89). Key stats such as the average daily volume over the past year has been around 407.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Daix, None, Inventiva S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew Obenshain, the company employs approximately 114 people and listed since July 10, 2020. Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

IVA has shown sold momentum, gaining 17.98% over the past week and 32.58% over the past quarter, though year-to-date performance is up 38.28%. Short-term trend indicators are bearishly aligned (SMA20 -6.33%, SMA50 13.03%, SMA200 31.16%). The stock’s 14-day RSI is 48.9 (neutral), while the ATR of 0.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -27.34% below its high and over 159.95% above its low. Average 10-day trading volume of 455.80 thousand shares is slightly above the 3-month average of 390.11 thousand, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Inventiva S.A. generated EPS of -$4.08 over the past year. Five-year average earnings growth is -18.31%. Wall Street analysts project EPS growth of 40.02% annually over the next five years. The latest quarter delivered EPS of -$1.90. The next quarter is forecast at -$0.30. Next year's EPS is expected at $12.99. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $9.00. The high target offers 348.28% upside. The low target suggests 55.17% downside. The mean target is $15.69. This offers 170.52% upside. Inventiva S.A. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended September 25, 2025, missed forecasts by 363.48%. The prior quarter beat by 472.95%. Over the last six quarters, Apple has recorded several small beats. These include 208.03% in March 27, 2024.

Inventiva S.A. has 139.06 million shares outstanding. The public float is 45.54 million shares, elevated short interest at 0.01% of float. This equals 10.01 thousand shares. The short ratio is 0.59 days. Institutional investors hold 5.16% of the float. Insiders own 0.0%.